Physician profile
Jeffrey A Mcdougall
NPI 1922089218
$1,294.74
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $507 · 2020: $247 · 2021: $372 · 2022: $169.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $430.89 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $170.03 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $120.83 | 2019 | |
| Merck Sharp & Dohme LLC | $96.21 | 2019-2021 | |
| Pfizer INC. | $86.89 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $70.89 | 2022 | |
| Astellas Pharma US INC | $63.00 | 2021-2022 | |
| Glaxosmithkline, LLC. | $49.23 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.58 | 2019-2020 | |
| Lilly USA, LLC | $40.61 | 2019-2021 | |
| Amarin Pharma, INC. | $35.81 | 2019-2020 | |
| Sanofi Pasteur INC. | $33.95 | 2019 | |
| Novo Nordisk INC | $27.01 | 2019-2020 | |
| Esperion Therapeutics, INC. | $25.81 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Mcdougall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.